Anna Alyasova

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Idiopathic pulmonary fibrosis

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

Measuring the multifaceted roles of mucin-domain glycoproteins in cancer

Revealing the human mucinome

Cancer-associated mucins: role in immune modulation and metastasis

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

VEGF in Signaling and Disease: Beyond Discovery and Development

Glycosylation in cancer: mechanisms and clinical implications

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.